How would you treat a young patient with metastatic colorectal cancer who initially tolerated 12 cycles of FOLFOX + bev with disease progression after cycle 3 of maintenance 5-FU + bev?

G1 neuropathy and G3 neutropenia were observed with cycle 12 FOLFOX + bev.

Would you reintroduce oxali at a lower dose or switch to irinotecan+EGFRi then retry FOLFOX+bev or EGFRi as third line?

Answer from: Medical Oncologist at Academic Institution

TRIBE and TRIBE2 studies showed convincing evidence of triplet chemotherapy FOLFOXIRI/bevacizumab has PFS, and more importantly, OS benefits for patients with metastatic colorectal cancer (mCRC) and now, this regimen has been used in our routine clinical practice more and more frequently especially ...

Comments

Medical Oncologist at Montefiore Einstein Comprehensive Cancer Center
Thank you. Patient is RAS WT. Planning to do irino...

Medical Oncologist at Mayo Clinic
You are right. I would give FOLFIRI with panitumum...

Please select the option that best describes you:

How would you treat a young patient with metastatic colorectal cancer who initially tolerated 12 cycles of FOLFOX + bev with disease progression after cycle 3 of maintenance 5-FU + bev?

Related Questions